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Biotinidase deficiency (BD) is a biotin responsive,
autosomal recessive inherited neurocutaneous, treatable
metabolic disorder. It occurs due to the deficiency of an
enzyme biotinidase, which is involved in biotin cycle. As a
result of BD the vitamin biotin is not recycled in biotin cycle.
The deficiency of biotinidase can be partial or profound based
on the level of activity of biotinidase enzyme; it is considered
as partial BD when biotinidase activity is 10-30% of mean
normal serum enzyme activity and profound BD when it is
less than 10% mean serum enzyme activity.
Untreated individuals with profound BD usually
manifest neurological and cutaneous features mostly between
second and fifth month of life.1 However, some patients can
present in late adolescent or even in adult life. Neurological
manifestations include hypotonia, developmental delay,
ataxia, sensorineural hearing impairment, optic atrophy and
seizures. Seizures can be tonic-clonic, myoclonic, partial, or
infantile spasms and are often resistant to anti-convulsant
medicines.2 Cutaneous manifestations of BD include atopic
or seborrhic dermatitis, partial or complete alopecia and
fungal skin infections.3 Some individuals with untreated BD
develop metabolic decompensation resulting into severe
metabolic acidosis, lactic acidosis, ketosis and
hyperammonemia, which can progress to coma and death.
Most of these patients report to general paediatricians but
they may seek specialist care from neurology, dermatology or
ophthalmology; if symptoms are limited to these systems.
Almost all symptoms respond dramatically to oral biotin
expect optic atrophy, sensorineural hearing impairment and
development delay, which is usually irreversible. 
Global incidence of BD is 1 in 60,000 live births4
Even higher incidence is reported from countries like Turkey
and Saudi Arab where there is high rates of consanguinity. In
Pakistan incidence of BD is unknown. There are no cases
reported from Pakistan however a number of Pakistani
children living in other countries are reported to have BD.5-7
This signifies that BD is very much present in our country but
patients are not recognized and diagnosed locally due to lack
of awareness of the condition among physicians and absence
of local diagnostic facility. Biotinidase activity is reliably
measured in serum and plasma using either semiquantitative
flurometeric method using biotin 6-amidoquinoline as
substrate or semiquantitative colorimetric method using N-
biotinyl-p-aminobenzoic acid as substrate but is
unfortunately currently not available in Pakistan. 
Sometimes BD is clinically suspected by physicians
but their inability to make definite diagnosis due to
unavailability of diagnostic test in Pakistan leads to numerous
long-term consequences. As neither the physician nor the
patient is confident of the diagnosis, importance of
compliance to life-long treatment with oral biotin is neither
emphasized by the physician nor its significance completely
appreciated by the patient. This leads to erratic compliance
resulting into recurrence of symptoms within weeks to
months of stopping oral biotin contributing to both morbidity
and mortality. Treatment with inadequate dose of oral biotin
is also a commonly observed issue. Recommended dose of
oral biotin for children with BD is 5-20mg of biotin per day
independent of age and weight.8 Biotin tablets mostly
available locally are of 600microgram strength. Patients
require 10-40 tablets per day of this current (600 mcg)
formulation. Patients are often prescribed 1 tablet
(600microgram) two or three times a day. Such inadequate
dose doesn't result in amelioration of symptoms, which at
many a times results into loss of faith upon physicians clinical
competence among patients and their care takers.
Biotinidase deficiency has an inexpensive and reliable
screening test, it is easily treatable and has a high morbidity
and mortality in untreated cases. Therefore it is included in
national newborn screening programmes of all states of
United States and thirty other countries.9 There is known
significant intra-familial variation both in the spectrum as
well as the age of onset of BD.10 In the absence of national
newborn screening programme in Pakistan, physicians in
Pakistan must screen all first-degree relatives of individuals
with BD for BD and treated if they are found to be affected. 
Biotinidase deficiency is considered as one of the most
rewarding metabolic disorders to treat. Health care providers
need to be aware of the condition and should make efforts to
make definite diagnosis by getting biotinidase activity
estimation from overseas labs in order to ensure prompt
treatment, good compliance and proper counseling for the
need of life-long treatment. Biotinidase activity estimation can
be easily sent to overseas labs by collecting dried blood spots
on filter papers and sending through regular postal services.
However, the need for locally available facility for biotinidase
assay cannot be emphasized enough. All leading institutes of
Pakistan should look into the feasibility of biotinidase activity
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estimation testing, so that it is easily available locally. Ministry
of health or National Institute of Health should arrange for
biotinidase testing in Pakistan. Physician's awareness is the
most important step to properly identify and treat these
patients. Identification of a case must be followed by family
screening for early identification of cases. All affected
individuals need periodic life-long follow-ups including
hearing and visual assessments.
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